Study of Dotatate Imaging in Breast Cancer

Hoag Health Network

Status and phase

Active, not recruiting

Phase 2

Conditions

Breast Cancer Stage IV

Treatments

Drug: Copper-64 DOTATATE

Drug: Gallium-68 DOTATATE

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT05880394

163-22-CA

Details and patient eligibility

About

This will be a Phase 2 clinical trial to assess somatostatin receptor (SSTR) expression in Stage IV estrogen receptor positive (ER+) breast cancer using Gallium-68 DOTATATE or Copper-64 DOTATATE PET/CT.

Full description

Subjects with metastatic breast cancer are planned to be enrolled to undergo Gallium-68 DOTATATE or Copper-64 DOTATATE PET/CT imaging at one time point. SSTR uptake in metastatic lesions will be evaluated by independent central review (ICR). FDG PET and bone scans will also be performed within +/- 3 weeks of DOTATATE imaging.

The primary objective of this study is to evaluate uptake of Gallium-68 DOTATATE or Copper-64 DOTATATE in metastatic ER+ breast cancer lesions.

Enrollment

30 estimated patients

Sex

Female

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Age of at least 18 years at the time of signing the informed consent.
Biopsy proven, ER+, HER2 any, clinically progressive, Stage IV breast cancer requiring restaging.
For women of childbearing potential (WOCBP):

a. Negative serum pregnancy test within 48 hours of Ga-68-DOTATATE injection. A women is considered to be of childbearing potential if she is post-menarchal, has not reached postmenopausal state (≥ 12 continuous months of amenorrhea [no menstrual bleeding of any kind, including menstrual period, irregular bleeding, spotting, etc.] with no identified cause other than menopause), and has not undergone surgical sterilization (total hysterectomy, or bilateral tubal ligation or bilateral oophorectomy at least 6 weeks before taking study drug).
Willingness and ability to provide written informed consent prior to any study-specific assessments and procedures commence.

Exclusion criteria

Known hypersensitivity to Gallium-68 DOTATATE or Copper-64 DOTATATE, octreotate, or any of the excipients of Gallium-68 DOTATATE or Copper-64 DOTATATE
Current high-dose glucocorticoid (≥ 20 mg prednisone daily or equivalent); long acting SSA within the last 28 days; short acting SSA that cannot be interrupted for 24 hours.
Unable to perform PET/CT scans according to technical specifications and local guidelines.
Concurrent primary malignancy, except adequately treated carcinoma in situ, non-melanoma carcinoma of the skin or any other curatively treated malignancy that has achieved complete response and is not expected to require treatment for recurrence during participation in the study.
Current somatic or psychiatric disease/condition that may interfere with the objectives and assessments of the study.
Unable or unwilling to comply with the requirements of the study protocol.
Prior participation in any interventional clinical study within 30 days prior to SSTR PET/CT scan.